Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02020135 is registered in ClinicalTrials.gov with Progenics Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02020135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02020135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Progenics Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
March 31, 2015
Enrollment
9 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer